Home NDC 0078-1483-20 RHAPSIDO
Product NDC 0078-1483
Requested package NDC 0078-1483-20
11-digit product format 000781483
Labeler code 0078
Product ID 0078-1483_03fb4b82-836d-4847-a9b5-e5695da55c1c
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name remibrutinib
Dosage form TABLET
Route ORAL
Labeler Novartis Pharmaceuticals Corporation
Application NDA218436
Marketing category NDA
Marketing start 2025-09-30
Substance REMIBRUTINIB
Active strength 25 mg/1
Pharmacologic classes Bruton's Tyrosine Kinase Inhibitors [MoA], Kinase Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA]
NDC exclude flag No
Listing certified through 2027-12-31
Current FDA listing Yes Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N218436-001 RHAPSIDO REMIBRUTINIB 25MG TABLET / ORAL RLD, RS 2025-09-30
Orange Book patents# Current patent rows page 1 of 1 · 5 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N218436-001 10457647 2034-11-13 U-4280 2025-10-21 N218436-001 9512084 2034-11-13 Drug substance, Drug product 2025-10-21 N218436-001 12419889 2043-01-19 U-4281 2025-10-21 N218436-001 12751949 2043-12-09 U-4611 Drug substance, Drug product 2026-10-13 N218436-001 12751949 2043-12-09 U-4612 Drug substance, Drug product 2026-10-13
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 2 matching rows.
Application-product, Exclusivity code, Expiration table Application-product Exclusivity code Expiration N218436-001 I-1002 2029-10-06 N218436-001 NCE 2030-09-30
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-11-14 07:37:17 2026-10 N218436-001 RHAPSIDO 25MG TABLET / ORAL RLD, RS 2025-09-30 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N218436-001 RHAPSIDO 25MG TABLET / ORAL RLD, RS 2025-09-30 c2088c7a36db…2026-09-14 22:38:34 2026-08 N218436-001 RHAPSIDO 25MG TABLET / ORAL RLD, RS 2025-09-30 84e616aacf4f…2026-08-18 06:07:40 2026-07 N218436-001 RHAPSIDO 25MG TABLET / ORAL RLD, RS 2025-09-30 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N218436-001 RHAPSIDO 25MG TABLET / ORAL RLD, RS 2025-09-30 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N218436-001 RHAPSIDO 25MG TABLET / ORAL RLD, RS 2025-09-30 31067a03dcf5…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N218436-001 RHAPSIDO 25MG TABLET / ORAL RLD, RS 2025-09-30 a50c72e98297…
Observed Orange Book patent history# Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N218436-001 10457647 2034-11-13 U-4280 2025-10-21 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218436-001 9512084 2034-11-13 Drug substance, Drug product 2025-10-21 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218436-001 12419889 2043-01-19 U-4281 2025-10-21 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218436-001 12751949 2043-12-09 U-4611 Drug substance, Drug product 2026-10-13 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N218436-001 12751949 2043-12-09 U-4612 Drug substance, Drug product 2026-10-13 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N218436-001 10457647 2034-11-13 U-4280 2025-10-21 c2088c7a36db…2026-10-15 13:18:30 2026-09 N218436-001 9512084 2034-11-13 Drug substance, Drug product 2025-10-21 c2088c7a36db…2026-10-15 13:18:30 2026-09 N218436-001 12419889 2043-01-19 U-4281 2025-10-21 c2088c7a36db…2026-09-14 22:38:34 2026-08 N218436-001 10457647 2034-11-13 U-4280 2025-10-21 84e616aacf4f…2026-09-14 22:38:34 2026-08 N218436-001 9512084 2034-11-13 Drug substance, Drug product 2025-10-21 84e616aacf4f…2026-09-14 22:38:34 2026-08 N218436-001 12419889 2043-01-19 U-4281 2025-10-21 84e616aacf4f…2026-08-18 06:07:40 2026-07 N218436-001 10457647 2034-11-13 U-4280 2025-10-21 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218436-001 9512084 2034-11-13 Drug substance, Drug product 2025-10-21 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218436-001 12419889 2043-01-19 U-4281 2025-10-21 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N218436-001 10457647 2034-11-13 U-4280 2025-10-21 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N218436-001 9512084 2034-11-13 Drug substance, Drug product 2025-10-21 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N218436-001 12419889 2043-01-20 U-4281 2025-10-21 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N218436-001 10457647 2034-11-13 U-4280 2025-10-21 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N218436-001 9512084 2034-11-13 Drug substance, Drug product 2025-10-21 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N218436-001 12419889 2043-01-20 U-4281 2025-10-21 31067a03dcf5…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N218436-001 10457647 2034-11-13 U-4280 2025-10-21 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N218436-001 9512084 2034-11-13 Drug substance, Drug product 2025-10-21 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N218436-001 12419889 2043-01-19 U-4281 2025-10-21 a50c72e98297…
Observed Orange Book exclusivity history# Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
Finished product Yes
Brand name base RHAPSIDO
Listing expiration 2027-12-31 Active Ingredients# Ingredient, Strength table Ingredient Strength REMIBRUTINIB 25 mg/1
Harmonized UNII identifiers# UNII identifiers page 1 of 1 · 1 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination I7MVZ8HDNU Internal UNII lookup
Harmonized RxCUI identifiers# RxCUI identifiers page 1 of 1 · 2 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 2724392 Internal RxNorm lookup 2724398 Internal RxNorm lookup
Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 0078-1483-20 RHAPSIDO 60 in 1 BOTTLE TABLET 60 2 0078-1483-92 RHAPSIDO 30 in 1 BOTTLE TABLET 30 2 0078-1483-92 RHAPSIDO 2 in 1 CARTON TABLET 2 2 0078-1483-93 RHAPSIDO 30 in 1 BOTTLE TABLET 30 2
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Sample Exclude flag Status 0078-1483-20 00078148320 60 TABLET in 1 BOTTLE (0078-1483-20) 60 tablet 2025-09-30 No No Current